SynthesisBMC microbiology2022
Meta-analysis of 16S rRNA microbial data identified alterations of the gut microbiota in COVID-19 patients during the acute and recovery phases.
Synthesis in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association Between Gut Microbiota and Pneumonia Risk: A Systematic Review and Mendelian Randomization.International journal of medical sciences · 2025Pooled it
- Perturbations in gut and respiratory microbiota in COVID-19 and influenza patients: a systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- Gut microbiota impact on lung diseases: a mini review of clinical evidence.Infection and immunity · 2026Review
- Nutritional Approaches to Managing Brain Fog: Insights Into Neuroinflammation, the Gut-brain Axis, and Sleep.Current nutrition reports · 2026Review
- Microbiome-Metabolome Crosstalk as a Driver of COVID-19 Severity.Medical sciences (Basel, Switzerland) · 2026Article
- Persistent gut microbiota dysbiosis and metabolic remodeling after ceftriaxone exposure in mice: a cross-study re-analysis.Frontiers in cellular and infection microbiology · 2026Article
- Gut Microbiome Dysbiosis in COVID-19: A Systematic Review and Meta-Analysis of Diversity Indices, Taxa Alterations, and Mortality Risk.Microorganisms · 2025Review
- Microbiome and Long COVID-19: Current Evidence and Insights.International journal of molecular sciences · 2025Review
- Gut Microbiome dysbiosis and immune activation correlate with somatic and neuropsychiatric symptoms in COVID-19 patients.Journal of translational medicine · 2025Article
- Chronic inflammation in post-acute sequelae of COVID-19 modulates gut microbiome: a review of literature on COVID-19 sequelae and gut dysbiosis.Molecular medicine (Cambridge, Mass.) · 2025Review
- SARS-CoV-2 variants mediated tissue-specific metabolic reprogramming determines the disease pathophysiology in a hamster model.Brain, behavior, and immunity · 2025Article
- Molecular analysis of long COVID and new-onset diabetes mellitus: pathobiological relationships and current mechanistic views.Frontiers in endocrinology · 2025Review
- Stabilized and unstabilized sampling methods result in differential fecal 16S rRNA microbial sequencing results.PloS one · 2025Article
- Review
- In Silico Analysis of Probiotic Bacteria Changes Across COVID-19 Severity Stages.Microorganisms · 2024Article
- The Multiple Challenges of Nutritional Microbiome Research During COVID-19-A Perspective and Results of a Single-Case Study.Nutrients · 2024Article
- Disease-associated microbiome signature species in the gut.PNAS nexus · 2024Article
- Deciphering Microbial Shifts in the Gut and Lung Microbiomes of COVID-19 Patients.Microorganisms · 2024Article
- The Multisystem Impact of Long COVID: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Gut Microbiome Disruption Following SARS-CoV-2: A Review.Microorganisms · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDozens of studies have demonstrated gut dysbiosis in COVID-19 patients during the acute and recovery phases. However, a consensus on the specific COVID-19 associated bacteria is missing. In this study, we performed a meta-analysis to explore whether robust and reproducible alterations in the gut microbiota of COVID-19 patients exist across different populations.
methodsA systematic review was conducted for studies published prior to May 2022 in electronic databases. After review, we included 16 studies that comparing the gut microbiota in COVID-19 patients to those of controls. The 16S rRNA sequence data of these studies were then re-analyzed using a standardized workflow and synthesized by meta-analysis.
resultsWe found that gut bacterial diversity of COVID-19 patients in both the acute and recovery phases was consistently lower than non-COVID-19 individuals. Microbial differential abundance analysis showed depletion of anti-inflammatory butyrate-producing bacteria and enrichment of taxa with pro-inflammatory properties in COVID-19 patients during the acute phase compared to non-COVID-19 individuals. Analysis of microbial communities showed that the gut microbiota of COVID-19 recovered patients were still in unhealthy ecostates.
conclusionsOur results provided a comprehensive synthesis to better understand gut microbial perturbations associated with COVID-19 and identified underlying biomarkers for microbiome-based diagnostics and therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.